PDL reported earnings for Q216 and announced that the company would be suspending dividend payments until further notice. This follows the reduction in dividends that occurred in Q116. Management made this decision strategically to reallocate resources to capitalize on the current hostile financing environment that has increased the attractiveness of alternative deals. It will also be able to take advantage of big pharma divestments using Noden Pharma as a platform for commercialization.